Skip to main content
SpringerLink
Log in

Vandetanib

First Global Approval

  • R&D Insight Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). Regulatory submissions for this indication have been filed in the EU and Canada, with clinical development in malignant MTC ongoing in several other countries. Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer. Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development. This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II

Similar content being viewed by others

References

  1. US FDA. FDA Approves New Treatment for Rare Form of Thyroid Cancer. Media Release: 6 Apr 2011. Available from URL: http://www.fda.gov

  2. AstraZeneca. FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer. Media Release: 7 Apr 2011. Available from URL: http://www.astrazeneca-us.com

  3. AstraZeneca. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer. Media Release: 2 Dec 2010. Available from URL: http://www.astrazeneca.com

  4. AstraZeneca. FDA Grants Fast Track Designation for the Investigation of ZACTIMA(TM) (ZD6474) for the Treatment of Thyroid Cancer. Media Release: 02 Feb 2006. Available from URL: http://www.astrazeneca-us.com

  5. AstraZeneca. FDA grants ZD6474 (ZACTIMA™) orphan drug designation for the investigation of rare forms of thyroid cancer. Media Release: 31 Oct 2005. Available from URL: http://www.astrazeneca.com

  6. AstraZeneca. AstraZeneca Outlines Strategy to Further Strengthen Its Product Pipeline While Delivering Continued Sales and Earnings Growth. Media Release: 8 Jun 2006. Available from URL: http://www.astrazeneca.com

  7. AstraZeneca. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer. Media Release: 30 Jul 2009. Available from URL: http://www.astrazeneca-us.com

  8. AstraZeneca Ltd. AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC. Media Release: 28 Oct 2009. Available from URL: http://www.astrazeneca.com

  9. Kim T, Saunders M, Salazar R, et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus FOLFIRI in patients with advanced colorectal cancer. 2009 Gastrointestinal Cancers Symposium: abstr. 188, 15 Jan 2009. Available from URL: http://www.asco.org

  10. Yang TS, Oh DY, Guimbaud R, et al. Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer: a randomized, double-blind, placebo-controlled phase II study. 45th Annual Meeting of the American Society of Clinical Oncology: 189 abstr. 4084, 31 May 2009. Available from URL: http://www.abstract.asco.org. Chang-Gung Memorial Hospital, Taoyuan, Taiwan

  11. Wells Jr SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medually thyroid cancer. Journal of Clinical Oncology 2010 Feb 10; 28(5): 767–72

    Article  PubMed  CAS  Google Scholar 

  12. Ohe Y, Kiura K, Nakagawa K, et al. A randomized double-blind phase IIa dose-finding study of vandetanib in Japanese patients with NSCLC. Journal of Thoracic Oncology 2 (Suppl.): 466–467, No. 8, Aug 2007. National Cancer Center, Tokyo, Japan

  13. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 3369–3376, No. 9, 1 May 2005. Indiana University, Indianapolis, Indiana, USA

    Article  CAS  Google Scholar 

  14. Broutin S, Dupuy C, Caillou B, et al. In vitro and in vivo activity of vandetanib in a human medullary thyroid carcinoma model bearing a RET(C634W) activating mutation. 100th Annual Meeting of the American Association for Cancer Research: abstr. 1788, 19 Apr 2009. Available from URL: http://www.aacr.org. Institut Gustave Roussy, Villejuif, France

  15. Cesca M, Frapolli R, Scarlato S, et al. The effects of treament sequencing on the antitumor activity of vandetanib and paclitaxel in a model of ovarian carcinoma xenograft. 20th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: 39 abstr. 119, 22 Oct 2008. Available from URL: http://www.ecco-org.eu. Mario Negri Institute for Pharmacological Research, Milano, Italy

  16. American Association for Cancer Research (AACR). Scientists Report on Promising New Approaches to Induce Cancer Cell Suicide. Media Release: 20 Nov 2003. Available from URL: http://www.aacr.org

  17. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62: 7284–7290, 15 Dec 2002. AstraZeneca Mereside, Macclesfield, Cheshire, United Kingdom

    PubMed  CAS  Google Scholar 

  18. Blackhall F, O'Brien M, Schmid P, et al. A phase I study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. Journal of Thoracic Oncology 2010; 5(8): 1285–8

    Article  PubMed  Google Scholar 

  19. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small cell lung cancer. Journal of Clinical Oncology 2007 Sep 20; 25(27): 4270–7

    Article  PubMed  CAS  Google Scholar 

  20. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). [abstract 1007] Ann Oncol 21 (suppl 8): viii315

  21. Leboulleux S, Bastholt L, Krause TM, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or f; DTC): a randomized, double-blind phase II trial. [abstract 1008] Ann Oncol 21 (suppl 8): viii315

  22. Haddad RI, Krebs AD, Vasselli J, et al. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 6024, 30 May 2008. Available from URL: http://www.asco.org.AstraZenecaOncology

  23. Boer K, Lang I, Llombart-Cussac A, et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo controlled, randomized phase II study. Breast Cancer Research and Treatment 106 (Suppl. 1): 274 (plus poster) abstr. 6081, Dec 2007. Saint Margit Hospital, Budapest, Hungary

    Google Scholar 

  24. Horti J, Widmark A, Stenzl A, et al. A randomised double-blind placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 2009 Apr; 24(2): 175–80

    Article  PubMed  CAS  Google Scholar 

  25. Herbst RS, Sun Y, Eberhardt WEE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology 2010 July; 11: 619–26

    Article  PubMed  CAS  Google Scholar 

  26. Natale RB, Thongprasert S, Greco FA, et al. Phase III trials of vandetanib compared with erlotinib in patients with previously treated advanced non-small cell lung cancer. Journal of Clinical Oncology 2011 Mar 10; 29(8): 1059–66

    Article  PubMed  CAS  Google Scholar 

  27. De Boer RH, Arrieta Ó, Yang C-H, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011 Mar 10; 29(8): 1067–74

    Article  PubMed  Google Scholar 

  28. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small cell lung cancer: results from a two-part double-blind, randomized phase II study. Journal of Clinical Oncology 2009 May 20; 27(15): 25239

    Article  Google Scholar 

  29. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology 2008 Nov 20; 26(33): 5407–15

    Article  PubMed  CAS  Google Scholar 

  30. AstraZeneca. First Phase III Trial With Definitive Results in Advanced Medullary Thyroid Cancer Shows Statistically Significant Extension of Progression Free Survival for Patients. Media Release: 7 Jun 2010. Available from URL: http://www.astrazeneca.com

  31. Mayer EL, Isakoff SJ, Hannagan K, et al. A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. 31st Annual San Antonio Breast Cancer Symposium: abstr. 906,10 Dec 2008. Available from URL: http://www.sabcs.saci.org. Dana Faber Cancer Institute, Boston, Massachusetts, USA

Download references

Author information

Authors and Affiliations

  1. R&D Insight, Wolters Kluwer Pharma Solutions, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Helen Commander & Glenn Whiteside

  2. Adis, a Wolters Kluwer Business, Auckland, New Zealand

    Caroline Perry

Authors
  1. Helen Commander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glenn Whiteside
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenn Whiteside.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Commander, H., Whiteside, G. & Perry, C. Vandetanib. Drugs 71, 1355–1365 (2011). https://doi.org/10.2165/11595310-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11595310-000000000-00000

Keywords

Search

Navigation